.In December 2024:- AstraZeneca- A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect ...

A RECENT study examining real-world COPD treatment outcomes has highlighted safety concerns regarding single-inhaler triple therapy compared to the long-acting beta2-agonist (LABA) and inhaled ...

Inhalers and nebulizers play a key role in delivering medication to the lungs, making it easier for people with breathing issues like asthma or COPD to manage their symptoms. To get the best results ...

In 2024, the most-read news articles published on the website of The American Journal of Managed Care® included FDA approvals ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

“Pharmaceutical companies should not be able to use reformulating as an excuse to sidestep their promises to patients.” Twenty-five million Americans with asthma and 16 million Americans with COPD ...

Starting with the Brestri Aerosphere COPD inhaler (pending regulatory approval), AstraZeneca intends to transition all of its MDIs to this technology by 2030. “The work we are doing with ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine ... in combination with inhaled corticosteroids (ICS), so ...

Delivery of asthma medication with pressurized metered-dose inhalers is economical, effective, and convenient. This method of delivery is a critical part of the medical management program for most ...